Current Opinion in Endocrinology & Diabetes and Obesity最新文献_第6页

Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question. 家族性高胆固醇血症儿童检测和治疗的卫生经济学:筛查或不筛查已不再是问题。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2023-11-20 DOI: 10.1097/MED.0000000000000844

Clara Marquina, Jedidiah I Morton, Zanfina Ademi

{"title":"Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question.","authors":"Clara Marquina, Jedidiah I Morton, Zanfina Ademi","doi":"10.1097/MED.0000000000000844","DOIUrl":"10.1097/MED.0000000000000844","url":null,"abstract":"Purpose of review: Heterozygous familial hypercholesterolemia (HeFH) is one of the most common monogenic disorders and is safely treatable with lipid-lowering medication. However, most individuals with HeFH remain untreated and undetected, especially in paediatric populations where the potential for long-term therapeutic benefit is higher. Here, we review the recent literature on health economic outcomes for the detection and management of FH in children.Recent findings: A targeted literature review identified eight studies evaluating detection and management strategies for paediatric FH populations in the last 25 years. Most studies conducted modelled cost-effectiveness analyses to understand the long-term impact of these strategies on health outcomes and the financial impact on the healthcare system. All studies reported that detection and management of HeFH in paediatric populations was cost-effective, regardless of the age of the children. However, cost-effectiveness varied depending on the method of case ascertainment - targeted screening was generally cheaper overall, but less effective, than whole-of-population screening, although both methods were generally cost-effective.Summary: Detection and management of HeFH in paediatric populations is a cost-effective way to significantly lower the burden of disease later in life for these individuals. These strategies should be implemented across healthcare systems.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"84-89"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing genetic and environmental sources of cardiometabolic disease. 解决心脏代谢疾病的遗传和环境来源。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1097/MED.0000000000000855

Gerald F Watts, Dick C Chan

引用次数: 0

APOC3 siRNA and ASO therapy for dyslipidemia. APOC3 siRNA 和 ASO 治疗血脂异常。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2024-02-09 DOI: 10.1097/MED.0000000000000857

Jasmine Chebli, Miriam Larouche, Daniel Gaudet

{"title":"APOC3 siRNA and ASO therapy for dyslipidemia.","authors":"Jasmine Chebli, Miriam Larouche, Daniel Gaudet","doi":"10.1097/MED.0000000000000857","DOIUrl":"10.1097/MED.0000000000000857","url":null,"abstract":"Purpose of review: The aim of this review is to present the clinical indications of apolipoprotein C-III (apoC3) inhibition in the therapeutic arsenal for the treatment of lipid disorders and associated risks and to compare the most advanced modalities of apoC3 inhibition currently available or in development, specifically APOC3 antisense oligonucleotides (ASO) and small interfering RNA (siRNA).Recent findings: ApoC3 inhibition significantly decreases triglyceride levels by mechanisms coupling both lipoprotein lipase (LPL) upregulation and LPL-independent mechanisms. The main apoC3 inhibitors in advanced clinical development are the GalNAc-ASO olezarsen and the GalNAc-siRNA plozasiran. Clinical studies conducted with volanesorsen, the olezarsen precursor, showed a favorable effect on hepatic steatosis (nonalcoholic fatty liver disease, NAFLD). Olezarsen does not appear to be associated with the main side effects attributed to volanesorsen including thrombocytopenia. Plozasiran is in advanced clinical development and requires subcutaneous injection every 3 months and present to-date an efficacy and safety profile comparable to that of the monthly ASO.Summary: Inhibition of apoC3 is effective across all the spectrum of hypertriglyceridemia, might have a favorable effect on hepatic steatosis (NAFLD) and the effect of apoC3 inhibition on cardiovascular risk is not limited to its effect on plasma triglycerides. APOC3 GalNAc-conjugated ASO and siRNA are both effective in decreasing plasma apoC3 and triglyceride levels.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"70-77"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multifactorial chylomicronemia syndrome. 多因素乳糜微粒血症综合征。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2023-11-23 DOI: 10.1097/MED.0000000000000846

Alan Chait

{"title":"Multifactorial chylomicronemia syndrome.","authors":"Alan Chait","doi":"10.1097/MED.0000000000000846","DOIUrl":"10.1097/MED.0000000000000846","url":null,"abstract":"Purpose of review: The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment.Recent findings: There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment. New approaches to triglyceride lowering will help reduce the risk of pancreatitis, the major complication of MFCS.Summary: MCSF is a condition in which plasma triglyceride levels are severely elevated, usually to due exacerbation of common genetic forms of hypertriglyceridemia by secondary causes of hypertriglyceridemia and/or triglyceride-raising drugs. Triglyceride-induced pancreatitis can be prevented by markedly reducing triglyceride levels by treating secondary causes and/or eliminating of triglyceride-raising drugs, and by using triglyceride-lowering drugs, especially fibrates. MFCS also increases cardiovascular disease risk, for which lifestyle measures and drugs are required.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"78-83"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introduction. 编辑介绍。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1097/MED.0000000000000856

引用次数: 0

Assessing the contribution of plastic-associated obesogenic compounds to cardiometabolic diseases. 评估塑料相关致胖化合物对心脏代谢疾病的影响。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-04-01 Epub Date: 2023-12-06 DOI: 10.1097/MED.0000000000000852

Jacob Warger, Michaela Lucas, Andrew Lucas

{"title":"Assessing the contribution of plastic-associated obesogenic compounds to cardiometabolic diseases.","authors":"Jacob Warger, Michaela Lucas, Andrew Lucas","doi":"10.1097/MED.0000000000000852","DOIUrl":"10.1097/MED.0000000000000852","url":null,"abstract":"Purpose of review: To present recent evidence that strengthens the concept that exogenous pollutants contribute to adipose dysfunction and increased rates of disease and to highlight the ineffective regulation of this risk as industry switches to related but similarly toxic variants.Recent findings: Substitutes for common phthalates and the highly regulated bisphenol A (BPA) show similar deleterious effects on adipocytes. The well tolerated limit for BPA exposure has been reduced in Europe to below the level detected in recent population studies. Additionally, the role for BPA-induced inflammation mediated by interleukin 17a has been described in animal and human studies.Summary: Despite experimental and associative evidence that supports plastics and plastic associated chemicals deleteriously influencing adipose homeostatasis and contributing to metabolic diseases, structurally related alternate chemicals are being substituted by manufacturers to circumvent trailing regulatory actions.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"98-103"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138486949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating psychosocial and behavioral interventions into type 1 diabetes care. 将心理社会和行为干预纳入1型糖尿病护理。

IF 3.2 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-02-01 Epub Date: 2023-10-06 DOI: 10.1097/MED.0000000000000839

Elizabeth A Pyatak, Anya R Khurana

{"title":"Integrating psychosocial and behavioral interventions into type 1 diabetes care.","authors":"Elizabeth A Pyatak, Anya R Khurana","doi":"10.1097/MED.0000000000000839","DOIUrl":"10.1097/MED.0000000000000839","url":null,"abstract":"Purpose of review: To identify recent literature evaluating the efficacy of psychosocial and behavioral interventions for people with type 1 diabetes (T1D).Recent findings: Interventions generally produce benefits for psychosocial and behavioral outcomes, and some also positively impact glycemia. Addressing psychosocial concerns during routine provider visits had mixed results; some studies found that structured tools improved well being, while others found they could derail conversations, or contribute to worsening glycemia due to a lack of time to review medical concerns. Integrating behavioral health providers in routine care, however, had a positive impact on glycemic outcomes. Stepped care interventions show promise for both children and adults, as they maximize available resources while contributing to improved well being. Group interventions, delivered either virtually or in-person, demonstrated benefits for diabetes distress, depressive symptoms, family conflict, and health behaviors, but had limited impact on positive parenting skills. Gaps in the current literature include limited research among adults and no research among older adults, as well as a lack of pragmatic research emphasizing implementation of effective interventions.Summary: A wide range of interventions have demonstrated positive impacts on well being among people with T1D; more research is needed to identify strategies to routinely integrate psychosocial and behavioral support in clinical care.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"8-13"},"PeriodicalIF":3.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibrous dysplasia in children and its management. 儿童纤维结构不良及其治疗。

IF 2.6 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-02-01 Epub Date: 2023-11-27 DOI: 10.1097/MED.0000000000000847

Zubeyir Hasan Gun, Aleena Arif, Alison M Boyce

{"title":"Fibrous dysplasia in children and its management.","authors":"Zubeyir Hasan Gun, Aleena Arif, Alison M Boyce","doi":"10.1097/MED.0000000000000847","DOIUrl":"10.1097/MED.0000000000000847","url":null,"abstract":"Purpose of review: The purpose of this review is to provide a comprehensive overview into the diagnosis and management of fibrous dysplasia (FD) in children.Recent findings: FD is a mosaic disorder arising from somatic Gα s variants, leading to impaired osteogenic cell differentiation. Fibro-osseous lesions expand during childhood and reach final disease burden in early adulthood. The mainstay of treatment focuses on surgical correction of skeletal deformities, physiatric care, and medical management of associated hyperfunctioning endocrinopathies. Bisphosphonates may be helpful to treat bone pain, but do not alter lesion quality or progression. Emerging evidence suggests that the RANKL inhibitor denosumab may be effective in improving lesion activity and mineralization, however further studies are needed to determine the potential utility of this and other novel therapies, particularly in children with FD.Summary: Management of children with FD has unique challenges related to skeletal growth and age-related lesion progression. Inclusion of children in clinical research is critical to develop effective treatment strategies to treat FD lesions and prevent their development.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"60-66"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bone mass accrual in children. 儿童骨量的增加。

IF 2.6 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-02-01 Epub Date: 2023-11-27 DOI: 10.1097/MED.0000000000000849

Eugene Rodrick, Joseph M Kindler

{"title":"Bone mass accrual in children.","authors":"Eugene Rodrick, Joseph M Kindler","doi":"10.1097/MED.0000000000000849","DOIUrl":"10.1097/MED.0000000000000849","url":null,"abstract":"Purpose of review: Bone accrual during childhood and adolescence is critical for the attainment of peak bone mass and is a major contributing factor towards osteoporosis in later life. Bone mass accrual is influenced by nonmodifiable factors, such as genetics, sex, race, ethnicity, and puberty, as well as modifiable factors, such as physical activity and diet. Recent progress in bone imaging has allowed clinicians and researchers to better measure the morphology, density, and strength of the growing skeleton, thereby encompassing key characteristics of peak bone strength. In this review, the patterning of bone accrual and contributors to these changes will be described, as well as new techniques assessing bone mass and strength in pediatric research and clinical settings.Recent findings: This review discusses factors influencing peak bone mass attainment and techniques used to assess the human skeleton.Summary: The rate of bone accrual and the magnitude of peak bone mass attainment occurs in specific patterns varying by sex, race, ethnicity, longitudinal growth, and body composition. Physical activity, diet, and nutritional status impact these processes. There is a need for longitudinal studies utilizing novel imaging modalities to unveil factors involved in the attainment and maintenance of peak bone strength.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"53-59"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Legislation, medicine, and politics: care for gender diverse youth. 立法、医学和政治:关心性别多样化的青年。

IF 2.6 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-02-01 Epub Date: 2023-11-27 DOI: 10.1097/MED.0000000000000845

Stephanie Preston, Ximena Lopez

{"title":"Legislation, medicine, and politics: care for gender diverse youth.","authors":"Stephanie Preston, Ximena Lopez","doi":"10.1097/MED.0000000000000845","DOIUrl":"10.1097/MED.0000000000000845","url":null,"abstract":"Purpose of review: A recent increase in legislation in the United States prohibiting gender-affirming care (GAC) for transgender youth follows a wave of its politicization despite support from all pertinent mainstream medical associations. This review describes the standards of GAC for transgender youth, the origins of legislation prohibiting this care, a review of current legislation in the United States and a discussion on the impact on patients, providers, and the medical field.Recent findings: A critical evaluation of historical parallels and current organizations supporting this legislation reveals it stems not from concerns within the medical field but from political and religious interests. This intrusion sets a dangerous precedent, undermining evidence-based medicine, providers' ability to practice according to standards of care, and patients' and guardians' autonomy and medical decision-making. This wave of antitrans rhetoric and legislation has resulted in threats to health providers and hospitals, 'moral distress\" in providers, and migration of providers and patients from hostile states.Summary: Similar to antiabortion legislation, these legislative efforts will likely result in negative health outcomes and worsening disparities. The medical community must confront these forces directly through an understanding of the political and structural forces at play and adopting strategies to leverage collective power.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"43-52"},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138444260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0